Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)
AASLD LiverLearning®, Josep M Llovet, 144131
FGF19 immunostaining as biomarker for trial enrichment testing FGFR4 inhibitors in HCC
AASLD LiverLearning®, Agrin Moeini, 144134
PD-L1 expression in hepatocellular carcinoma: relationship with clinical and pathological features
AASLD LiverLearning®, Fouad LAFDIL, 144136
A Randomized, Prospective, Comparative Study about Effects and Safety of Sorafenib vs. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis
AASLD LiverLearning®, Wang Yong Choi, 144137
Changing epidemiology of hepatocellular carcinoma in Singapore - a study of 1,401 cases over 3 decades
AASLD LiverLearning®, Weiquan James Li, 144138
ALBI and PALBI Grade Predict Survival for HCC across Treatment Modalities and BCLC Stages in the MELD Era
AASLD LiverLearning®, Po-Hong Liu, 144141
The Molecular Progression Of Nonalcoholic Fatty Liver Disease
AASLD LiverLearning®, Sophie Cazanave, 144397
Year 2 serum HBV DNA detectability predicts hepatocellular carcinoma in entecavir-treated patients - a 7-year cohort study of 1,680 patients with chronic hepatitis B
AASLD LiverLearning®, Grace Wong, 144142
Usefulness of modified Japan Integrated Staging (JIS) score using albumin-bilirubin (ALBI) grade as a prognostic scoring system for hepatocellular carcinoma: analysis with 2584 Japanese patients
AASLD LiverLearning®, Hirofumi Izumoto, 144146
Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry
AASLD LiverLearning®, Su Jong Yu, 144149
The Role Of Serum Alphafetoprotein Determination In HCV-Cirrhosis After Antiviral Treatment
AASLD LiverLearning®, Cristina Della Corte, 144152
Development of a Novel Circulating Tumor Cells Isolation System in Patients with Hepatocellular Carcinoma Using a Microcavity Array
AASLD LiverLearning®, Kazuto Takahashi, 144153
Early decrease in alfafetoprotein as a prognosis factor of response in patients with advanced hepatocellular carcinoma treated with sorafenib
AASLD LiverLearning®, Teresa Ferrer Rios, 144157
Translating the ABC-02 trial into daily practice: Outcome of palliative treatment in patients with advanced biliary tract cancer treated with gemcitabine and cisplatin
AASLD LiverLearning®, Jeroen van Vugt, 144162
Circulating and intratumoral CD39+FoxP3+ regulatory T cells associate with disease progression in HCC patients
AASLD LiverLearning®, Junliang Fu, 144168
ALBI-T: A Score Based on Albumin, Bilirubin and TNM Stratifies Patients with Child A Cirrhosis and Hepatocellular Carcinoma
AASLD LiverLearning®, Imam Waked, 144169
Obeticholic acid reduces plasma HDL-cholesterol levels and promotes transhepatic cholesterol efflux in hyperlipidemic hamsters via a mechanism involving upregulation of hepatic SR-BI
AASLD LiverLearning®, Jingwen Liu, 144426
Modulation of HMGB1 - NF-κB translocation by curcumin treatment ameliorates liver injury in non-alcoholic steatohepatitis-hepatocellular carcinoma mouse model
AASLD LiverLearning®, MST. REJINA AFRIN, 144428
Vitamin K supplementation decreased the incidence of severe hand-foot skin reaction during sorafenib treatment for hepatocellular carcinoma.
AASLD LiverLearning®, Yoshimichi Haruna, 144173
BAP1 modulates expression of long non-coding RNA NEAT1 and contributes to cancer phenotype and sensitivity to gemcitabine in intrahepatic cholangiocarcinoma (iCCA)
AASLD LiverLearning®, Mansi Parasramka, 144176
The GALAD serological model may permit earlier diagnosis of hepatocellular carcinoma in a screened cirrhotic population: a re-analysis of a prospective trial
AASLD LiverLearning®, Hiroyuki Yamada, 144177
Gene Network Analysis Reveals a Novel 22-Gene Signature of Carbon Metabolism in Hepatocellular Carcinoma
AASLD LiverLearning®, jinqiang zhang, 144178
Pirfenidone LP activates PPARα and LXRα and results in decreased expression of proinflammatory cytokines and improvement of NASH features induced by high fat/carbohydrate diet
AASLD LiverLearning®, José Macías-Barragán, 144434
Liver microRNA hsa-miR-125a-5p exerts an oncosuppressor effect on hepatocellular carcinoma (HCC) regulating the expression of MMP11, c-Raf and SIRT7.
AASLD LiverLearning®, Nicola Coppola, 144179
Impact of age and race/ethnicity for women with gastrointestinal and hepatobiliary malignancies in the U.S.
AASLD LiverLearning®, Vicky Bhagat, 144182
Birth Cohort Analysis of Incidence, Mortality, Treatment modality and Survival of Hepatocellular Carcinoma in Surveillance, Epidemiology and End Results Registries, 1973-2012
AASLD LiverLearning®, Fanggang Liu, 144184
Changes in tissue and blood biomarkers upon exposure to sorafenib in patients with resectable HCC: translational evaluation in the BIOSHARE trial
AASLD LiverLearning®, Valérie Paradis, 144185
A cohort study of Hepatocellular Adenoma in post-menopausal women: can follow-up be safely terminated?
AASLD LiverLearning®, Anne Klompenhouwer, 144187
Role of Aberrant NDRG3 Expression in Human Hepatocellular Carcinoma
AASLD LiverLearning®, Jin Jeong, 144189
Barcelona Clinic Liver Cancer (BCLC) Versus Hong Kong Liver Cancer (HKLC) Staging Systems in an Asian Tertiary Centre - A review of 1270 patients from a multiracial Asian population
AASLD LiverLearning®, Weiquan James Li, 144190
Dietary Cholesterol Intake Is Not Associated with Hepatocellular Carcinoma Development or Chronic Liver Disease Related Death in the General Population: The United States Multiethnic Cohort
AASLD LiverLearning®, Lei Yu, 144191
Calcium sensing receptor activation increases triglyceride accumulation in HepG2 cells
AASLD LiverLearning®, Pia Villarroel, 144448
Patients with Nonalcoholic Steatohepatitis Cirrhosis Are Significantly Less Likely To Receive Appropriate Screening for Hepatocellular Carcinoma Compared to Patients with Chronic Hepatitis C Virus Cirrhosis
AASLD LiverLearning®, Hesam Tavakoli, 144193
Platinum-based transhepatic arterial chemotherapy using a combination of miriplatin and CDDP powder in patients with hepatocellular carcinoma
AASLD LiverLearning®, Kohei Ogawa, 144194
Therapeutic option as an alternative strategy for a solitary (3-5 cm) hepatocellular carcinoma; an analysis of a nationwide cancer registry database
AASLD LiverLearning®, Young-Joo Jin, 144195
Portal Hypertension SIG: Hypercoagulability in Cirrhosis: Program Chair : Introductory Remarks
AASLD LiverLearning®, Cristina Ripoll, 154693
IL-33, released with hepatectomy, facilitated CCA prognosis
AASLD LiverLearning®, Daisaku Yamada, 144199
The Utility of a Multidisciplinary Liver Tumor Clinic (MDTC) to Treat Patients with Hepatocellular Carcinoma (HCC) at a Large Volume Liver Transplant Center
AASLD LiverLearning®, Ravi Vora, 144200
Impact of Age, Gender, and Race/Ethnicity on Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in the U.S.
AASLD LiverLearning®, Vicky Bhagat, 144201
Safety, Tolerability and Pharmacokinetics of L-Ornithine Phenylacetate in Patients with Acute Liver Injury/Failure
AASLD LiverLearning®, Richard Stravitz, 154954
Phenotypical characterization of intrahepatic cholangiocarcinomas : the more fibrous, the less pejorative.
AASLD LiverLearning®, Lorraine Blaise, 144203
SCCA-IgM helps to identify patients at risk of long-term hepatocelullar carcinoma
AASLD LiverLearning®, Javier Ampuero, 144204
Hepatobiliary Neoplasia SIG: NASH and HCC: Program Chair
AASLD LiverLearning®, Lopa Mishra, 154703
Insulin resistance assessment is useful in risk stratification of hepatocellular carcinoma in chronic hepatitis B patients
AASLD LiverLearning®, jung hee kim, 144208
The GLP-1 analogue, liraglutide, reduces NAFLD Activity Score and Fibrosis Stage and improves metabolic parameters in a diet-induced obese mouse model of biopsy-confirmed nonalcoholic steatohepatitis (NASH)
AASLD LiverLearning®, Kirstine Tølbøl, 144467
Nucleos(t)ide analogues improved survival of CHB-related HCC patients
AASLD LiverLearning®, wang yun, 144212
Patients’ misconceptions about surveillance for hepatocellular carcinoma: Education is needed.
AASLD LiverLearning®, Faydra Lieveld, 144213
Intrahepatic Cholangiocarcinoma Presenting as LI-RADS 5 'HCC'
AASLD LiverLearning®, Raja Koteswar Dhanekula, 144214
Endoglin Antibody Reduces the NAFLD Activity Score in the STAM Model of NASH and Reduces Liver Fibrosis Following Carbon Tetrachloride Treatment
AASLD LiverLearning®, Charles Theuer, 144471
Quality of Life and Outcomes after Multiple Courses of Granulocyte-Colony Stimulating Factor and Growth Hormone in Patients with Decompensated Cirrhosis
AASLD LiverLearning®, Virendra Singh, 154967
High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis
AASLD LiverLearning®, Helder Cardoso, 144219
Spexin, a novel regulator of lipid & carbohydrate metabolism, is a potential therapeutic for obesity, type 2 diabetes mellitus, & non-alcoholic fatty liver disease.
AASLD LiverLearning®, Paul Berk, 154971
Endoscopic duodenal mucosal resurfacing (DMR) improves insulin sensitivity, hepatic transaminase levels and anti-inflammatory markers in type 2 diabetes subjects
AASLD LiverLearning®, Harith Rajagopalan, 154973
A single endoscopic duodenal mucosal resurfacing procedure exerts a sustained improvement in hepatic transaminase levels in a cohort of type 2 diabetes patients
AASLD LiverLearning®, Annieke van Baar, 154974
Discovery of new non-invasive tests algorithms (NITs-Algo) for liver disease in subjects with metabolic factors, using SAF scoring system. A proof of concept demonstrating the impact of disease definitions.
AASLD LiverLearning®, Thierry Poynard, 154975
Improvement in NASH histological activity highly correlates with fibrosis regression.
AASLD LiverLearning®, Vlad Ratziu, 154976
ALBI grade versus Child-Pugh grade as a grading system for liver function in patients with hepatocellular carcinoma
AASLD LiverLearning®, Seong Kyun Na, 144225
Survival analysis of single large (>5 cm) hepatocellular carcinoma patients: BCLC A versus B
AASLD LiverLearning®, Su Jong Yu, 144228
The sustained virologic response achieved by PegIFN/RBV could significantly improve survival of intermediate stage CHC-HCC patients receiving TACE
AASLD LiverLearning®, Wei Teng, 144229
The Expression of SALL4 and Its Clinical Significance In Hepatocellular Carcinoma.
AASLD LiverLearning®, Zhiying Xin, 144233
The features of hepatocellular carcinoma after IFN free treatment
AASLD LiverLearning®, Masataka Seike, 144234
Comparison of liver pathology in three rodent NASH models to that observed in human NASH patients
AASLD LiverLearning®, Robert Walczak, 144490
Hepatitis B and C as Risk Factors for Early Hepatocellular Carcinoma Across South America
AASLD LiverLearning®, Jose Debes, 144235
Validation of tumor factor of staging systems in hepatocellular carcinoma; focusing on the difference between each staging system
AASLD LiverLearning®, Sadahisa Ogasawara, 144238
Regional differences in admissions and treatment outcomes for patients with hepatocellular carcinoma (HCC) in Thailand: data from the national universal health care
AASLD LiverLearning®, Ml.Taya Kitiyakara, 144246
Outcome of treatment in BCLC-0/A HCC patients in real world practice: impact of treatment response and treatment stage migration in overall survival (OS)
AASLD LiverLearning®, Alessia Gazzola, 144247
Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma
AASLD LiverLearning®, Young Mi Hong, 144248
Xenobiotic metabolism in a mouse model of non-alcoholic fatty liver disease: A case study of the ubiquitous environmental contaminant tetrachloroethylene
AASLD LiverLearning®, Joseph Cichocki, 144506
Outcomes of a new very small diameter drug eluting embolic beads for transarterial chemoembolization in unresectable hepatocellular carcinoma.
AASLD LiverLearning®, Mohamed Shoreibah, 144252
Risk of Hepatocellular Carcinoma after Antiviral Therapy in Different Sets of Korean Patients with Chronic Hepatitis C
AASLD LiverLearning®, Sangyoung Yi, 144254
Yttrium-90 (90Y) Radioembolization in the treatment of intrahepatic cholangiocarcinoma (ICC): Preprocedural biomarkers of response
AASLD LiverLearning®, Xiao Jing Wang, 144255
Saroglitazar attenuates hepatic inflammation, oxidative stress and fibrosis in models of NAFLD/NASH
AASLD LiverLearning®, Mukul Jain, 144511
Low long term tumor recurrence and mortality rates in patients transplanted for hepatocellular carcinoma listed with low native MELD scores
AASLD LiverLearning®, Heather O'Dell, 144257
Liver Transplantation for Hepatocellular carcinoma: Results from a Multicenter Cohort from Latin America.
AASLD LiverLearning®, Federico Piñero, 144259
Real-life Adherence to BCLC Therapeutic Algorithm of Hepatocellular carcinoma in a Multicenter cohort from Argentina.
AASLD LiverLearning®, Federico Piñero, 144260
In Hepatocytes, DNA Methylation and Hydroxymethylation Are Altered in Response to Oleic Acid Exposure: A Potential Mechanism for Non-alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Zobair Younossi, 144516
The efficacy of radiofrequency ablation combined with transcatheter hepatic chemoembolization for patients with BCLC stage B hepatocellular carcinoma: A multicenter retrospective study-propensity score matching
AASLD LiverLearning®, Masashi Hirooka, 144261
Factors Associated with Misdiagnosis of Hepatocellular Carcinoma before Liver Transplant with No Tumors Found on Explant: An Analysis of the UNOS database
AASLD LiverLearning®, Neil Mehta, 144269
Significant of Hepatectomy for Stage B and C Hepatocellular Carcinoma in the BCLC Classification
AASLD LiverLearning®, Toshiya Kamiyama, 144270
Liver Transplantation after Share 35: Impact on Pre- and Post-Transplant Costs and Mortality
AASLD LiverLearning®, Clara Nicolas, 144279
Sarcopenia in children awaiting liver transplantation.
AASLD LiverLearning®, Eberhard Lurz, 144289
Multicenter Study on Down-staging of Hepatocellular Carcinoma for Liver Transplantation: Is Down-staging Failure due to the Tumor or the Long Waiting time?
AASLD LiverLearning®, Neil Mehta, 144291
Expanding the Utilization of Metabolic Livers for Domino Transplantation: Successful Domino Liver Transplant from a Patient with Propionic Acidemia
AASLD LiverLearning®, Nadia Ovchinsky Nadia, 144293
Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure (ACLF) with Hepatic Encephalopathy (HE): A Randomized Trial (ClinicalTrials.gov Identifier: NCT02321371)
AASLD LiverLearning®, Anand Kulkarni, 144301
Bone Forming cells are Decreased in Osteopenic and Osteoporostic Conditions in Cirrhosis Patients.
AASLD LiverLearning®, Chhagan Bihari, 144302
Critical Flicker Frequency predicts progression among stages of cirrhosis
AASLD LiverLearning®, Javier Ampuero, 144307
Total Skeletal Muscle Compared to Psoas Muscle Evaluation for the Assessment of Sarcopenia in Cirrhosis: A Multi-Center Study from the FLEXIT Consortium
AASLD LiverLearning®, Aldo J Montano-Loza, 144313
Comparative effectiveness of different pharmacological interventions for the treatment of minimal hepatic encephalopathy: A Systematic review with network meta-analysis
AASLD LiverLearning®, Radha Dhiman, 144314
Oral glutamine challenge predicts and identifies long-term ammonia-related overt hepatic encephalopathy
AASLD LiverLearning®, Javier Ampuero, 144318
Hyperosmolality is Independently Associated with Severity of Hepatic Encephalopathy in Patients Admitted to Intensive Care Units with Acutely Decompensated Liver Function
AASLD LiverLearning®, Eric Liotta, 144321
Genomic Characterization of Stool Microbiota With Rifaximin Monotherapy Versus Lactulose Combination Therapy for Prevention of Overt Hepatic Encephalopathy (HE) Recurrence
AASLD LiverLearning®, Herbert DuPont, 144333
Hepatitis due to HBV reactivation in chronic hepatitis B and C co-infected Chinese treated with direct-acting antivirals
AASLD LiverLearning®, Cheng Wang, 144352
Corticosteroids are the only remaining pharmacological option for severe alcoholic hepatitis: a meta-analysis of individual data on 1974 patients.
AASLD LiverLearning®, Philippe MATHURIN, 144097
Assessment of nutritional status through bioelectrical impedance is a key determinant of outcome in alcoholic hepatitis: a prospective study
AASLD LiverLearning®, Laurent Spahr, 144098
Fecal microbiota transplantation (FMT) improves outcome and survival in steroid ineligible severe alcoholic hepatitis–A randomized control trial (NCT 02458079)
AASLD LiverLearning®, Cyriac Philips, 155632
The Sofosbuvir (SOF) and Velpatasvir (VEL) Regimen is Associated with High Efficacy and Improvement of Patient-Reported Outcomes (PROs) in Patients Co-infected with Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV): The Data from ASTRAL-5
AASLD LiverLearning®, Zobair Younossi, 144369
Plasma cytokines predict faster viral load decline in patients with chronic hepatitis C treated with direct-acting antivirals - an exploratory analysis
AASLD LiverLearning®, Cheng Wang, 144373
HBV replication increases cholesterols via upregulation of SREBP-2/HMGCR and down-regulation of CYP-7α in alcoholic fatty liver mice
AASLD LiverLearning®, Hongwu Wang, 144120
HLA-E molecule expression in the liver is associated with severity of liver disease in chronic hepatitis C
AASLD LiverLearning®, Patrícia Almeida, 144376
Therapeutic Potential Of Liver X Receptor (LXR) In Alcoholic Liver Disease (ALD)
AASLD LiverLearning®, Monideepa Sengupta, 144126